Shots:

• Janssen gets license to utilize physIQ’s accelerateIQ platform to gather data from clinical studies through different wearable biosensors. The platform is powered by FDA-cleared digital biomarkers that helps to transform raw data into clinical insight
• The platform’s findings can be used to advance subsequent research projects and will support both R&D and commercial strategies
• The collaboration will boost the ability to bring new treatments to market and enable commercial strategies that integrate digital medicine into patient care

  Ref: Business Wire | Image: Janssen